竞争风险分析揭示肿瘤与非肿瘤患者股骨远端置换翻修累积发生率差异
本研究回顾性纳入1983至2016年229例股骨远端置换患者,采用竞争风险分析评估翻修累积发生率,并比较肿瘤与非肿瘤患者的差异。结果显示所有患者12个月翻修累积发生率为26%,10年为58.2%;肿瘤患者翻修风险低于非肿瘤患者(HR 0.44),且肿瘤患者骨水泥固定可降低翻修风险(HR 0.53)。
要点
- 股骨远端置换后翻修累积发生率高,10年达58.2%。
- 肿瘤患者翻修风险低于非肿瘤患者(HR 0.44)。
- 肿瘤患者骨水泥固定可降低翻修风险(HR 0.53)。
核心结论
- 股骨远端置换后翻修发生率高,即使使用新型假体亦然。
- 肿瘤诊断患者骨水泥固定可降低翻修风险,非肿瘤患者固定方式无影响。
- 肿瘤与非肿瘤患者应分别进行生存分析。
研究设计与样本
- 回顾性纳入1983至2016年229例股骨远端置换患者,中位随访85个月(范围0.1-391个月)。
- 采用竞争风险分析(死亡为竞争事件)估计翻修累积发生率,并使用Fine和Gray模型进行单因素和多因素分析。
主要发现
- 所有患者翻修累积发生率:12个月26%(95% CI,20.3%-31.9%),24个月37.9%(95% CI,31.3%-44.4%),5年52.6%(95% CI,45.1%-59.5%),10年58.2%(95% CI,50.1%-65.4%)。
- 旋转铰链假体5年翻修累积发生率为41.6%(95% CI,31.8%-51%),低于固定铰链假体的64%(95% CI,50.5%-74.5%)(Gray检验p=0.01)。
- 多因素分析显示肿瘤患者翻修风险低于非肿瘤患者(HR 0.44;95% CI,0.22-0.87;p=0.02)。
- 肿瘤患者骨水泥固定降低翻修风险(HR 0.53;95% CI,0.29-0.98;p=0.03)。
- 手术年份对翻修风险无影响(1994-2003年HR 0.70;95% CI,0.46-1.07;2004-2016年HR 0.83;95% CI,0.52-1.34;p=0.26)。
关键数值与推荐
- 翻修原因采用国际保肢学会分类系统。
- 竞争风险分析中死亡作为竞争事件。
临床怎么用
- 临床应分别评估肿瘤与非肿瘤患者的翻修风险。
- 对肿瘤患者可考虑骨水泥固定以降低翻修风险。
- 旋转铰链假体可能优于固定铰链假体。
局限性
- 回顾性研究设计。
- 无固定假体选择算法,骨水泥固定患者年龄较大。
- 随访时间跨度大,手术技术和假体设计可能变化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Distal femur replacement is frequently used for limb salvage after bone tumor resections. It is also used in patients with severe bone loss because of traumatic conditions or revision TKA. Some studies on distal femur replacement reported on revision-free survival without distinguishing between patients with oncologic diagnoses and those without, although these patients might be incomparable because of their differences in important patient- and disease-specific characteristics. This may lead to an inaccurate and undifferentiated interpretation of the results of survival analyses. QUESTIONS/PURPOSES: (1) What is the overall cumulative incidence of revision surgery after cemented and cementless distal femoral replacement, as determined with a competing risk analysis? (2) Does the cumulative incidence of revision surgery change over time? (3) Are there differences in the cumulative incidence of revision surgery between patients with oncologic conditions and those without who are treated with cemented or cementless distal femoral replacement? METHODS: A total of 403 patients were possible candidates for distal femoral replacement. Of these, 56 patients elected to undergo different procedures, 83 were excluded because an expendable growing prosthesis was implanted, and 28 were lost to follow-up. Therefore, 229 patients who underwent distal femoral replacement for oncologic or non-oncologic reasons between 1983 and 2016 were retrospectively included in this study. The type of fixation method (cemented or cementless) was obtained from the patients' medical records, operation reports, and radiographic analyses from plain radiographs. All radiographs were standardized and obtained at standard time intervals in our institution. No algorithm regarding the fixation approach was followed. According to our data, patients receiving cementless fixation were younger and therefore likely to be more active than those receiving cemented fixation. The median follow-up duration of the overall cohort was 85 months (range 0.1-391 months). Patients who died or had revision surgery before the 2-year minimum follow-up interval were adequately considered using competing risk calculation. The reasons for revision surgery were classified using the classification system proposed by the International Society for Limb Salvage. A competing risk analysis was performed to estimate the cumulative incidence function of revision, accounting for death as a competing event. To evaluate the influence of potential prognostic factors, including diagnosis (oncologic versus non-oncologic), fixation (cemented versus cementless), year of distal femoral replacement, age, and sex on the occurrence of revision surgery, univariate and multivariable Fine and Gray models were applied. RESULTS: The competing risks analysis revealed cumulative incidences of revision surgery for any cause (Types 1 to 5) of 26% (95% CI, 20.3%-31.9%) at 12 months, 37.9% (95% CI, 31.3%-44.4%) at 24 months, 52.6% (95% CI, 45.1%-59.5%) at 5 years, and 58.2% (95% CI, 50.1%-65.4%) at 10 years for all patients. Rotating hinge-type prostheses showed a lower cumulative incidence of revision surgery (41.6%; 95% CI, 31.8%-51%) than fixed-hinge prostheses did (64%; 95% CI, 50.5%-74.5% ) at 5 years (Gray's test: p = 0.01). According to the multivariate Fine and Gray model, the year of surgery did not have any effect on the risk of revision surgery (1994 to 2003: hazard ratio 0.70; 95% CI, 0.46-1.07); 2004 to 2016: HR 0.83; 95% CI, 0.52-1.34; p = 0.26). The multivariate analysis, adjusted for disease, sex, age, cementation, and year of surgery, revealed a difference in the risk of revision surgery between patients with oncologic disease and those with non-oncologic disease (HR 0.44 for oncologic versus non-oncologic; 95% CI, 0.22-0.87; p = 0.02) and a reduction in the risk of overall revision with cemented fixation in patients with oncologic disease (HR 0.53; 95% CI, 0.29-0.98; p = 0.03). CONCLUSION: This study indicates that even with newer implants, there was a high incidence of revision surgery after distal femoral replacement. According to our analysis, patients with oncologic diagnoses have a lower likelihood of revision when the stem is cemented whereas the type of fixation did not impact patients with non-oncologic diagnoses. Because of differences in patient demographics (age, etiology of disease, and use of chemotherapy) and outcomes of fixation, oncologic and non-oncologic patients should be analyzed separately in survival studies about distal femoral replacement. LEVEL OF EVIDENCE: Level III, therapeutic study.
引用
- Staats K, Vertesich K, Sigmund IK, et al. Does a Competing Risk Analysis Show Differences in the Cumulative Incidence of Revision Surgery Between Patients with Oncologic and Non-oncologic Conditions After Distal Femur Replacement? Clin Orthop Relat Res. 2020. PMID: 31895069. doi:10.1097/CORR.0000000000001106
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。